ID   FM3
AC   CVCL_2046
SY   FM-3
DR   Cosmic; 808544
DR   Cosmic; 851400
DR   Cosmic; 1047663
DR   ECACC; 13012407
DR   GEO; GSM156042
DR   IARC_TP53; 26090
DR   Progenetix; CVCL_2046
DR   Wikidata; Q54835025
RX   PubMed=7656272;
RX   PubMed=7899823;
RX   PubMed=8665567;
RX   PubMed=8968104;
RX   PubMed=9288767;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=23851445;
CC   HLA typing: A*02,03; B*07,44 (PubMed=7656272).
CC   HLA typing: A*02:01; B*07:02,44:02; C*05:01; DPB1*04:01; DQB1*06:02,03:01:01; DRB1*04:01:01,15:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; PubMed=23851445).
CC   Omics: Array-based CGH.
CC   Derived from metastatic site: Right inguinal lymph node.
ST   Source(s): ECACC; ESTDAB
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 12
ST   D16S539: 12,13
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 10
ST   FGA: 23
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 18
RX   PubMed=7656272; DOI=10.1007/BF01527402;
RA   Kirkin A.F., Petersen T.R., Olsen A.C., Li L., thor Straten P.,
RA   Zeuthen J.;
RT   "Generation of human-melanoma-specific T lymphocyte clones defining
RT   novel cytolytic targets with panels of newly established melanoma cell
RT   lines.";
RL   Cancer Immunol. Immunother. 41:71-81(1995).
RX   PubMed=7899823; DOI=10.1111/j.1365-3083.1995.tb03579.x;
RA   Olsen A.C., Fossum B., Kirkin A.F., Zeuthen J., Gaudernack G.;
RT   "A human melanoma cell line, recognized by both HLA class I and class
RT   II restricted T cells, is capable of initiating both primary and
RT   secondary immune responses.";
RL   Scand. J. Immunol. 41:357-364(1995).
RX   PubMed=8665567; DOI=10.1007/s002620050272;
RA   Kirkin A.F., thor Straten P., Zeuthen J.;
RT   "Differential modulation by interferon gamma of the sensitivity of
RT   human melanoma cells to cytolytic T cell clones that recognize
RT   differentiation or progression antigens.";
RL   Cancer Immunol. Immunother. 42:203-212(1996).
RX   PubMed=8968104;
RA   Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F.,
RA   Zeuthen J., Bartek J.;
RT   "The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently
RT   altered in melanoma pathogenesis.";
RL   Cancer Res. 56:5475-5483(1996).
RX   PubMed=9288767;
RA   Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F.,
RA   Zeuthen J.;
RT   "Disruption of the MMAC1/PTEN gene by deletion or mutation is a
RT   frequent event in malignant melanoma.";
RL   Cancer Res. 57:3660-3663(1997).
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).